Literature DB >> 32442262

Ethical and Practical Issues Associated With the Possibility of Using Controlled Human Infection Trials in Developing a Hepatitis C Virus Vaccine.

Andrea Cox1,2, Mark Sulkowski1, Jeremy Sugarman1,2,3.   

Abstract

Despite the existence of established treatments for hepatitis C virus (HCV), more effective means of preventing infection, such as a vaccine, are arguably needed to help reduce substantial global morbidity and mortality. Given the expected challenges of developing such a vaccine among those at heightened risk of infection, controlled human infection studies seem to be a promising potential approach to HCV vaccine development, but they raise substantial ethical and practical concerns. In this article, we describe some of the challenges related to the possibility of using controlled human infection studies to accelerate HCV vaccine development. The related ethical and practical concerns require further deliberation before such studies are planned and implemented.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  challenge studies; controlled human infection studies; ethics; hepatitis C virus; vaccines

Mesh:

Substances:

Year:  2020        PMID: 32442262      PMCID: PMC7778335          DOI: 10.1093/cid/ciaa640

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   20.999


  46 in total

1.  Ethical Criteria for Human Challenge Studies in Infectious Diseases.

Authors:  Ben Bambery; Michael Selgelid; Charles Weijer; Julian Savulescu; Andrew J Pollard
Journal:  Public Health Ethics       Date:  2015-09-27       Impact factor: 1.940

Review 2.  Hepatitis C virus vaccines among people who inject drugs.

Authors:  Andrea L Cox; David L Thomas
Journal:  Clin Infect Dis       Date:  2013-08       Impact factor: 9.079

Review 3.  A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs.

Authors:  Holly Hagan; Enrique R Pouget; Don C Des Jarlais
Journal:  J Infect Dis       Date:  2011-07-01       Impact factor: 5.226

4.  The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection.

Authors:  Jason Grebely; Kimberly Page; Rachel Sacks-Davis; Maarten Schim van der Loeff; Thomas M Rice; Julie Bruneau; Meghan D Morris; Behzad Hajarizadeh; Janaki Amin; Andrea L Cox; Arthur Y Kim; Barbara H McGovern; Janke Schinkel; Jacob George; Naglaa H Shoukry; Georg M Lauer; Lisa Maher; Andrew R Lloyd; Margaret Hellard; Gregory J Dore; Maria Prins
Journal:  Hepatology       Date:  2013-11-22       Impact factor: 17.425

Review 5.  Candidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunities.

Authors:  Lisa Maher; Bethany White; Margaret Hellard; Annie Madden; Maria Prins; Thomas Kerr; Kimberly Page
Journal:  Vaccine       Date:  2010-09-09       Impact factor: 3.641

6.  Prospective evaluation of community-acquired acute-phase hepatitis C virus infection.

Authors:  Andrea L Cox; Dale M Netski; Timothy Mosbruger; Susan G Sherman; Steffanie Strathdee; Danielle Ompad; David Vlahov; David Chien; Venkatakrishna Shyamala; Stuart C Ray; David L Thomas
Journal:  Clin Infect Dis       Date:  2005-03-03       Impact factor: 9.079

Review 7.  Sexually transmitted hepatitis C infection: the new epidemic in MSM?

Authors:  Daniel Bradshaw; Gail Matthews; Mark Danta
Journal:  Curr Opin Infect Dis       Date:  2013-02       Impact factor: 4.915

8.  Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study.

Authors:  Alexei Zelenev; Jianghong Li; Alyona Mazhnaya; Sanjay Basu; Frederick L Altice
Journal:  Lancet Infect Dis       Date:  2017-11-15       Impact factor: 25.071

9.  Hepatitis C in Injection-Drug Users - A Hidden Danger of the Opioid Epidemic.

Authors:  T Jake Liang; John W Ward
Journal:  N Engl J Med       Date:  2018-03-29       Impact factor: 91.245

10.  More rare birds, and the occasional swan.

Authors:  Brian R Edlin; Marla A Shu; Emily Winkelstein; Don C Des Jarlais; Michael P Busch; Barbara Rehermann; Thomas R O'Brien; Andrew H Talal; Leslie H Tobler; Marija Zeremski; Ann B Beeder
Journal:  Gastroenterology       Date:  2009-05-03       Impact factor: 22.682

View more
  1 in total

Review 1.  To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity.

Authors:  Felicia Schlotthauer; Joey McGregor; Heidi E Drummer
Journal:  Viruses       Date:  2021-04-30       Impact factor: 5.048

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.